US5094941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies to PDGF
Assignee: Zymogenetics Inc
•
Filing: 1987-12-31
•
Granted: 1992-03-10
•
Expires: 2007-12-31
Abstract
Abstract Monoclonal antibodies (MAbs) capable of binding to native PDGF, and MAbs capable of specifically binding to the PDGF-AA, PDGF-BB and PDGF-AB isoforms are disclosed. The subject MAbs may be used in the detection or purification of native PDGF or selected PGDF isoforms. In addition, the MAbs may be labeled with an imaging agent and used for in vivo diagnostic purposes, or combined with a pharmaceutically acceptable carrier or diluent for use within wound healing compositions.
Inventors
- 👤 Charles E. Hart
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 13:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/49; C07K16/00; C07K16/18; C07K16/22; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/80; C12N15/81; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S435/975; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/824; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 66
Claim 1
Independent Claim
10 words
A monoclonal antibody that specifically binds to the PDGF-BB isoform.
Claim 2
Dependent Claim
10 words
A monoclonal antibody that specifically binds to the PDGF-BB isoform.
Claim 3
Dependent Claim
20 words
The monoclonal antibody of claim 1 wherein said antibody is tagged with a label capable of providing a detectable signal.
Claim 4
Dependent Claim
16 words
The monoclonal antibody of claim 1 wherein the antibody is of the subclass IgG 1 .
Claim 5
Dependent Claim
30 words
The monoclonal antibody of claim 1 wherein said antibody blocks the binding of an antibody produced by cell line 120.1.2.1.2, assigned ATCC Accession No. HB 9610, to the PDGF-BB isoform.
Claim 6
Dependent Claim
10 words
The cell line 120.1.2.1.2, assigned ATCC Accession No. HB 9610.
Claim 7
Dependent Claim
10 words
The cell line 120.1.2.1.2, assigned ATCC Accession No. HB 9610.
Claim 8
Dependent Claim
11 words
A monoclonal antibody produced by the cell line of claim 5.
Claim 9
Dependent Claim
10 words
A monoclonal antibody that specifically binds to the PDGF-AA isoform.
Claim 10
Dependent Claim
10 words
A monoclonal antibody that specifically binds to the PDGF-AA isoform.
Claim 11
Dependent Claim
16 words
The monoclonal antibody of claim 7 wherein the antibody is of the subclass IgG 2b .
Claim 12
Dependent Claim
30 words
The monoclonal antibody of claim 8 wherein said antibody blocks the binding of an antibody produced by cell line 127.8.2.2.2, assigned ATCC Accession No. HB 9611, to the PDGF-AA isoform.
Claim 13
Dependent Claim
10 words
The cell line 127.8.2.2.2, assigned ATCC Accession No. HB 9611.
Claim 14
Dependent Claim
10 words
The cell line 127.8.2.2.2, assigned ATCC Accession No. HB 9611.
Claim 15
Dependent Claim
11 words
A monoclonal antibody produced by the cell line of claim 10.
Claim 16
Dependent Claim
14 words
A monoclonal antibody that specifically binds to the PDGF-AB isoform and the PDGF-BB isoform.
Claim 17
Dependent Claim
14 words
A monoclonal antibody that specifically binds to the PDGF-AB isoform and the PDGF-BB isoform.
Claim 18
Dependent Claim
20 words
The monoclonal antibody of claim 12 wherein said antibody is tagged with a label capable of providing a detectable signal.
Claim 19
Dependent Claim
16 words
The monoclonal antibody of claim 12 wherein the antibody is of the subclass IgG 1 .
Claim 20
Dependent Claim
34 words
The monoclonal antibody of claim 12 wherein said antibody blocks the binding of an antibody produced by cell line 121.6.1.1.1, assigned ATCC Accession No. HB 9613 to the PDGF-AB isoform or the PDGF-BB isoform.
Claim 21
Dependent Claim
10 words
The cell line 121.6.1.1.1, assigned ATCC Accession No. HB 9613.
Claim 22
Dependent Claim
10 words
The cell line 121.6.1.1.1, assigned ATCC Accession No. HB 9613.
Claim 23
Dependent Claim
11 words
A monoclonal antibody produced by the cell line of claim 16.
Claim 24
Dependent Claim
14 words
A monoclonal antibody that specifically binds to the PDGF-AB isoform and the PDGF-AA isoform.
Claim 25
Dependent Claim
14 words
A monoclonal antibody that specifically binds to the PDGF-AB isoform and the PDGF-AA isoform.
Claim 26
Dependent Claim
16 words
The monoclonal antibody of claim 18 tagged with a label capable of providing a detectable signal.
Claim 27
Dependent Claim
16 words
The monoclonal antibody of claim 18 wherein the antibody is of the subclass IgG 1 .
Claim 28
Dependent Claim
34 words
The monoclonal antibody of claim 18 wherein said antibody blocks the binding of an antibody produced by cell line 127.5.7.3.1, assigned ATCC Accession No. HB 9612, to the PDGF-AB isoform or the PDGF-AA isoform.
Claim 29
Dependent Claim
9 words
The cell line 127.5.7.3.1, assigned ATCC Accession No. 9612.
Claim 30
Dependent Claim
9 words
The cell line 127.5.7.3.1, assigned ATCC Accession No. 9612.
Claim 31
Dependent Claim
11 words
A monoclonal antibody produced by the cell line of claim 22.
Claim 32
Independent Claim
57 words
A method for determining the presence of the PDGF-BB isoform in a biological sample, comprising: incubating a monoclonal antibody that is capable of specifically binding to the PDGF-BB isoform with a biological sample; and detecting the presence of immune-complexes formed between said monoclonal antibody and said biological sample, and therefrom determining the presence of the PDGF-BB isoform.
Claim 33
Independent Claim
57 words
A method for determining the presence of the PDGF-BB isoform in a biological sample, comprising: incubating a monoclonal antibody that is capable of specifically binding to the PDGF-BB isoform with a biological sample; and detecting the presence of immune-complexes formed between said monoclonal antibody and said biological sample, and therefrom determining the presence of the PDGF-BB isoform.
Claim 34
Dependent Claim
30 words
The method of claim 24 wherein said monoclonal antibody blocks the binding of an antibody produced by cell line 120.1.2.1.2, assigned ATCC Accession No. HB 9610, to the PDGF-BB isoform.
Claim 35
Dependent Claim
22 words
The method of claim 24 wherein said monoclonal antibody is produced by the cell line 120.1.2.1.2, assigned ATCC Accession No. HB 9610.
Claim 36
Dependent Claim
11 words
The method of claim 24 wherein the monoclonal antibody is labeled.
Claim 37
Dependent Claim
20 words
The method of claim 27 wherein said label is selected from the group consisting of radionuclides, fluorophores, enzymes and luminescers.
Claim 38
Dependent Claim
24 words
The method of claim 27 wherein the step of detecting is by measurement of radioactivity, fluorescence, enzyme reaction or luminescence emission of said label.
Claim 39
Dependent Claim
39 words
The method of claim 24 wherein the biological sample is selected from the group consisting of blood, urine, plasma, serum, platelet and other cell lysates, platelet releasates, cell suspensions, cell-conditioned culture media and chemically or physically separated portions thereof.
Claim 40
Dependent Claim
32 words
The method of claim 24 including, after the step of incubating, incubating the monoclonal antibody/sample with a labeled antibody that is capable of binding to the PDGF-BB isoform or the monoclonal antibody.
Claim 41
Independent Claim
57 words
A method for determining the presence of the PDGF-AA isoform in a biological sample, comprising: incubating a monoclonal antibody that is capable of specifically binding to the PDGF-AA isoform with a biological sample; and detecting the presence of immune-complexes formed between said monoclonal antibody and said biological sample, and therefrom determining the presence of the PDGF-AA isoform.
Claim 42
Independent Claim
57 words
A method for determining the presence of the PDGF-AA isoform in a biological sample, comprising: incubating a monoclonal antibody that is capable of specifically binding to the PDGF-AA isoform with a biological sample; and detecting the presence of immune-complexes formed between said monoclonal antibody and said biological sample, and therefrom determining the presence of the PDGF-AA isoform.
Claim 43
Dependent Claim
28 words
The method of claim 32 wherein said monoclonal antibody blocks the binding of an antibody produced by cell line 127.8.2.2.2, assigned ATCC Accession No. HB 9611, to PDGF.
Claim 44
Dependent Claim
22 words
The method of claim 32 wherein said monoclonal antibody is produced by the cell line 127.8.2.2.2, assigned ATCC Accession No. HB 9611.
Claim 45
Dependent Claim
11 words
The method of claim 32 wherein the monoclonal antibody is labeled.
Claim 46
Dependent Claim
20 words
The method of claim 35 wherein said label is selected from the group consisting of radionuclides, fluorophores, enzymes and luminescers.
Claim 47
Dependent Claim
24 words
The method of claim 35 wherein the step of detecting is by measurement of radioactivity fluorescence, enzyme reaction or luminescence emission of said label.
Claim 48
Dependent Claim
39 words
The method of claim 32 wherein the biological sample is selected from the group consisting of blood, urine, plasma, serum, platelet and other cell lysates, platelet releasates, cell suspensions, cell-conditioned culture media and chemically or physically separated portions thereof.
Claim 49
Dependent Claim
33 words
The method of claim 32 including, after the step of incubating, incubating the monoclonal antibody/sample with a second labeled antibody that is capable of binding to the PDGF-AA isoform or the monoclonal antibody.
Claim 50
Independent Claim
159 words
A method for purifying native PDGF from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to native PDGF, selected from the group consisting of antibodies that block the binding of an antibody produced by cell line 120.1.2.1.2 (ATCC Accession No. HB 9610) to the PDGF-BB isoform, antibodies that block the binding of an antibody produced by cell line 127.8.2.2.2 (ATCC Accession No. HB 9611) to the PDGF-AA isoform, antibodies that block the binding of an antibody produced by cell line 121.6.1.1.1 (ATCC Accession No. HB 9613) to the PDGF AB isoform or the PDGF-BB isoform, and antibodies that block the binding of an antibody produced by cell line 127.5.7.3.1 (ATCC Accession No. HB 9612) to the PDGF-AB isoform or the PDGF-AA isoform, on a substrate; contacting the sample containing native PDGF with the immobilized monoclonal antibodies under suitable conditions such that the native PDGF binds to said antibodies; and eluting the native PDGF from the monoclonal antibodies.
Claim 51
Independent Claim
159 words
A method for purifying native PDGF from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to native PDGF, selected from the group consisting of antibodies that block the binding of an antibody produced by cell line 120.1.2.1.2 (ATCC Accession No. HB 9610) to the PDGF-BB isoform, antibodies that block the binding of an antibody produced by cell line 127.8.2.2.2 (ATCC Accession No. HB 9611) to the PDGF-AA isoform, antibodies that block the binding of an antibody produced by cell line 121.6.1.1.1 (ATCC Accession No. HB 9613) to the PDGF AB isoform or the PDGF-BB isoform, and antibodies that block the binding of an antibody produced by cell line 127.5.7.3.1 (ATCC Accession No. HB 9612) to the PDGF-AB isoform or the PDGF-AA isoform, on a substrate; contacting the sample containing native PDGF with the immobilized monoclonal antibodies under suitable conditions such that the native PDGF binds to said antibodies; and eluting the native PDGF from the monoclonal antibodies.
Claim 52
Dependent Claim
22 words
The method of claim 40 wherein the substrate is selected from the group consisting of polymeric tubes, beads, polysaccharide particulates, and polyacrylamide.
Claim 53
Dependent Claim
38 words
The method of claim 40 wherein the sample is selected from the group consisting of blood, urine, plasma, serum, platelet and other cell lysates, platelet releasates, cell suspensions, cell-conditioned culture media and chemically or physically separated portions thereof.
Claim 54
Dependent Claim
19 words
The method of claim 40 including, after the step of contacting, separating unbound sample from the immobilized monoclonal antibodies.
Claim 55
Independent Claim
57 words
A method for purifying the PDGF-BB isoform from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to the PDGF-BB isoform, on a substrate; contacting the sample containing native PDGF with the immobilized monoclonal antibodies under suitable conditions such that the PDGF-BB isoform binds to said antibodies; and eluting the PDGF-BB isoform from the monoclonal antibodies.
Claim 56
Independent Claim
57 words
A method for purifying the PDGF-BB isoform from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to the PDGF-BB isoform, on a substrate; contacting the sample containing native PDGF with the immobilized monoclonal antibodies under suitable conditions such that the PDGF-BB isoform binds to said antibodies; and eluting the PDGF-BB isoform from the monoclonal antibodies.
Claim 57
Dependent Claim
19 words
The method of claim 44 including, after the step of contacting, separating unbound sample from the immobilized monoclonal antibodies.
Claim 58
Independent Claim
58 words
A method for purifying the PDGF-AA isoform from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to the PDGF-AA isoform, on a substrate; contacting the sample containing the PDGF-AA isoform with the immobilized monoclonal antibodies under suitable conditions such that the PDGF-AA isoform binds to said antibodies; and eluting the PDGF-AA isoform from the monoclonal antibodies.
Claim 59
Independent Claim
58 words
A method for purifying the PDGF-AA isoform from a sample, comprising: immobilizing monoclonal antibodies, capable of specifically binding to the PDGF-AA isoform, on a substrate; contacting the sample containing the PDGF-AA isoform with the immobilized monoclonal antibodies under suitable conditions such that the PDGF-AA isoform binds to said antibodies; and eluting the PDGF-AA isoform from the monoclonal antibodies.
Claim 60
Dependent Claim
19 words
The method of claim 46 including, after the step of contacting, separating unbound sample from the immobilized monoclonal antibodies.
Claim 61
Dependent Claim
164 words
A diagnostic kit for assaying the presence of native PDGF, comprising, in a suitable package; a monoclonal antibody, capable of binding to native PDGF, selected from the group consisting of an antibody that blocks the binding of an antibody produced by cell line 120.1.2.1.2 (ATCC Accession No. HB 9610) to the PDGF-BB isoform, an antibody that blocks the binding of an antibody produced by cell line 127.8.2.2.2 (ATCC Accession No. HB 9611) to the PDGF-AA isoform, an antibody that blocks the binding of an antibody produced by cell line 121.6.1.1.1 (ATCC Accession No. HB 9613) to the PDGF AB isoform or the PDGF-BB isoform, and an antibody that blocks the binding of an antibody produced by cell line 127.5.7.3.1 (ATCC Accession No. HB 9612) to the PDGF-AB isoform or the PDGF-AA isoform, and a labeled polyclonal antibody that is capable of binding to native PDGF wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
Claim 62
Dependent Claim
164 words
A diagnostic kit for assaying the presence of native PDGF, comprising, in a suitable package; a monoclonal antibody, capable of binding to native PDGF, selected from the group consisting of an antibody that blocks the binding of an antibody produced by cell line 120.1.2.1.2 (ATCC Accession No. HB 9610) to the PDGF-BB isoform, an antibody that blocks the binding of an antibody produced by cell line 127.8.2.2.2 (ATCC Accession No. HB 9611) to the PDGF-AA isoform, an antibody that blocks the binding of an antibody produced by cell line 121.6.1.1.1 (ATCC Accession No. HB 9613) to the PDGF AB isoform or the PDGF-BB isoform, and an antibody that blocks the binding of an antibody produced by cell line 127.5.7.3.1 (ATCC Accession No. HB 9612) to the PDGF-AB isoform or the PDGF-AA isoform, and a labeled polyclonal antibody that is capable of binding to native PDGF wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
Claim 63
Dependent Claim
60 words
A diagnostic kit for assaying the presence of the PDGF-BB isoform, comprising, in a suitable package: a monoclonal antibody capable of specifically binding to the PDGF-BB isoform, and a labeled polyclonal antibody that is capable of binding to the PDGF-BB isoform wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
Claim 64
Dependent Claim
60 words
A diagnostic kit for assaying the presence of the PDGF-BB isoform, comprising, in a suitable package: a monoclonal antibody capable of specifically binding to the PDGF-BB isoform, and a labeled polyclonal antibody that is capable of binding to the PDGF-BB isoform wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
Claim 65
Dependent Claim
60 words
A diagnostic kit for assaying the presence of the PDGF-AA isoform, comprising, in a suitable package: a monoclonal antibody capable of specifically binding to the PDGF-AA isoform, and a labeled polyclonal antibody that is capable of binding to the PDGF-AA isoform wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
Claim 66
Dependent Claim
60 words
A diagnostic kit for assaying the presence of the PDGF-AA isoform, comprising, in a suitable package: a monoclonal antibody capable of specifically binding to the PDGF-AA isoform, and a labeled polyclonal antibody that is capable of binding to the PDGF-AA isoform wherein the monoclonal antibody and the polyclonal antibody are contained within the same or separate containers within said package.
References Cited (Backward Citations)
WO1981002899A1
Cited
US4376110A
Cited
US4415665A
Cited
US4479896A
Cited
WO1985000807A1
Cited
US4689220A
Cited
US4769328A
Cited
US4801542A
Cited
US4766073A
Cited
US4845075A
Cited
US4849407A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-10 | 1995-09-09 | 1996-03-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-10 | 1999-09-09 | 2000-03-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-10 | 2003-09-09 | 2004-03-10 | $7700.00 | Window Closed / Lapsed |